NVST

Let’s dig into the relative performance of Envista (NYSE:NVST) and its peers as we unravel the now-completed Q1 dental equipment & technology earnings season. The dental equipment and technology industry encompasses companies that manufacture orthodontic products, dental implants, imaging systems, and digital tools for dental professionals. These companies benefit from recurring revenue streams tied to consumables, ongoing maintenance, and growing demand for aesthetic and restorative dentistry. However, high R&D costs, significant capital investment requirements, and reliance on discretionary spending make them vulnerable to economic cycles. Over the next few years, tailwinds for the sector include innovation in digital workflows, such as 3D printing and AI-driven diagnostics, which enhance the efficiency and precision of dental care. However, headwinds include economic uncertainty, which could reduce patient spending on elective procedures, regulatory challenges, and potential pricing pressures from consolidated dental service organizations (DSOs). The 4 dental equipment & technology stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 3% while next quarter’s revenue guidance was in line. Thankfully, share prices of the companies have been resilient as they are up 5.6% on average since the latest earnings results. Uniting more than 30 trusted brands including Nobel Biocare, Ormco, and DEXIS under one corporate umbrella, Envista Holdings (NYSE:NVST) is a global dental products company that provides equipment, consumables, and specialized technologies for dental professionals. Envista reported revenues of $705.5 million, up 14.4% year on year. This print exceeded analysts’ expectations by 4.5%. Overall, it was a strong quarter for the company with a beat of analysts’ EPS estimates. "We delivered a good start to 2026, with first quarter results reflecting continued strong execution and progress in support of our strategic priorities," said Paul Keel, CEO. Envista achieved the fastest revenue growth of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 4.2% since r...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Envista Holdings stock sits at an interesting valuation crossroads, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while traditional market multiples suggest the shares are not obviously cheap, all against a backdrop of mixed long term returns. Envista Holdings has declined 38.5% over the past 5 years, which raises the question of whether the current valuation reflects a reset in expectations or an opportunity if the business outlook holds up. The company’s focus on expanding its product portfolio and customer reach can support revenue and cash flow over time. However, macroeconomic and geopolitical pressures may weigh on how confident investors feel about paying up for that growth. Envista scores just 2 out of 6 on broader valuation checks, which leans more toward the stock looking expensive on several measures rather than a straightforward bargain. The issue now is whether Envista Holdings’ current share price already reflects its growth ambitions, or if the DCF implied discount of 38.1% signals a margin of safety that the market is overlooking. Envista Holdings delivered 24.3% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry. The Discounted Cash Flow (DCF) model values Envista Holdings by projecting future cash generation and discounting it back to today. Envista’s latest twelve month free cash flow is about $224.9 million, with the model assuming that cash flows continue growing from this base rather than shrinking. Using these inputs, the 2 Stage Free Cash Flow to Equity approach arrives at an estimated intrinsic value of about $41.59 per share in dollar terms. Compared with the current share price, that estimate implies Envista Holdings stock is about 38.1% undervalued. Because Envista has been highlighted for ongoing expansion efforts and reaffirmed guidance, the recent news around acquisitions and growth plans helps explain why some investors may see the current discount as a reflection of execution risk rather than a lack of potential. On balance, the DCF analysis indicates that Envista Holdings appears undervalued relative to what its projected cash flows could justify. Our Discounted Cash Flow (DCF) analysis suggests Envi...

BREA, Calif., July 7, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its second quarter 2026 on Wednesday, August 5, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You can access the conference call by dialing 1-800-836-8184 within the U.S. or +1 646-357-8785 outside the U.S. a few minutes before 2:00 PM PT and referencing Conference ID #73468. Envista's earnings press release, the webcast slides, and other related presentation materials will be posted to the "Investors" section of Envista's website before the conference call and will remain available following the call. ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global leader in the dental industry, uniting more than 30 trusted brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission: partnering with dental professionals to improve patients' lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years. Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System. Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services that empower clinicians to provide confident, efficient care—today and for the future. Learn more at http://envistaco.com. FOR FURTHER INFORMATIONJim GustafsonVice President, Investor RelationsEnvista Holdings Corporation200 S. Kraemer Blvd., Building EBrea, CA 92821Telephone: (424) [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/envista-schedules-second-quarter-2026-earnings-call-302819440.html

It has been about a month since the last earnings report for Envista (NVST). Shares have lost about 5.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Envista due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Envista Holdings Corporation before we dive into how investors and analysts have reacted as of late. Revenues: $705.5 million in first quarter 2026, up 14.4% YoY Adjusted Diluted EPS: $0.36 in first quarter 2026, up 50.0% YoY GAAP Diluted EPS: $0.23 in first quarter 2026, up 130.0% YoY Adjusted Gross Margin: 55.8% in first quarter 2026, up 100 bps YoY GAAP Operating Margin: 8.9% in first quarter 2026, up 260 bps YoY Specialty Products & Technologies Revenue: $457.8 million in first quarter 2026, up 14.4% YoY Equipment & Consumables Revenue: $247.7 million in first quarter 2026, up 14.4% YoY. Envista reported adjusted earnings per share (EPS) of 36 cents in the first quarter of 2026, up 50% year over year. The adjustments include non-cash charges related to the amortization of acquisition-related and other intangible assets, restructuring costs and asset impairments, among others. The company’s GAAP earnings were 23 cents compared with the year-ago quarter’s 10 cent per share. Specialty Products & Technologies revenues totaled $457.8 million in first-quarter 2026, up 14.4% year over year. The segment generated operating profit of $46.5 million and an operating margin of 10.2%, representing an 80-basis-point improvement from 9.4% in the first quarter of 2025. Core sales growth was 8.4% in the quarter. Equipment & Consumables revenues totaled $247.7 million in first-quarter 2026, up 14.4% year over year. The segment generated operating profit of $46.8 million and an operating margin of 18.9%, an improvement of 420 basis points from 14.7% in the prior-year quarter. Core sales growth was 11.5% in the period, reflecting healthy demand in developed markets. Adjusted gross margin expanded 100 basis points to 55.8%, supported by volume, price, productivity, and favorable FX. Operating expense growth remained controlled relative to revenues. Selling, general and administrative expenses increased 9.5% year over year to $297.6 million, and research and development spending rose...

Envista Corporation NVST has started to rebuild investor confidence, but the valuation question is still front and center. The stock trades at 15.1x forward 12-month earnings, a modest premium to its Zacks sub-industry at 14.9x, and a discount to the Zacks sector at 19.6x and the S&P 500 at 22.2x. Image Source: Zacks Investment Research With shares at $22.94 and a $24 price target tied to a 16.2x forward 12-month earnings multiple, the setup is about whether recent execution can hold long enough to justify a slightly higher multiple. The market is assigning Envista 15.1x forward 12-month earnings. That level sits close to the sub-industry’s 14.9x, implying investors are not yet paying up for a decisive re-rating. At the same time, the discount to the sector (19.6x) and the S&P 500 (22.2x) suggests expectations remain restrained. The $24 price target is anchored to a 16.2x forward 12-month earnings multiple, which is only modestly above today’s trading level. Put differently, the upside case is not dependent on a big multiple expansion. It depends on Envista sustaining the operating improvements now showing up in results. Envista shares are up 5.7% year to date and up 22.3% over the past year. That performance looks more constructive when set against a weak peer backdrop: the Zacks sub-industry is down 25.2% year to date and down 30.9% over the past year, while the Zacks Medical sector is down 6.6% year to date and up 2.7% over the past year. Benchmark dispersion matters because multiples are forward-looking reflections of market expectations. A sub-industry drawdown can compress peer multiples even if fundamentals differ, while a more resilient sector line can keep sector-level valuations elevated. Against that backdrop, Envista’s near-sub-industry multiple reads less like “cheapness” and more like a market that wants proof the recent momentum is repeatable. The first quarter of 2026 showed meaningful profit acceleration alongside solid top-line growth. Revenue was $705.5 million, up 14.4% year over year. Adjusted diluted earnings per share were $0.36, up 50% year over year, while GAAP diluted earnings per share were $0.23. The quality of the improvement matters. Adjusted gross margin expanded 100 basis points to 55.8%, supported by volume, price, productivity and favorable foreign exchange. Operating expenses also grew more slowly than revenue, with selling...

Envista’s first quarter results saw sales increase driven by strong growth across orthodontics, diagnostics, and consumables, supported by new product launches and operational improvements. However, the negative market reaction reflected investor caution, as management pointed to macroeconomic uncertainty and the impact of tariffs as ongoing challenges. CEO Paul Keel noted the company’s gains “were partly due to improved execution in growth, operations, and people,” while also acknowledging the benefits from additional billing days and focused cost controls. Is now the time to buy NVST? Find out in our full research report (it’s free). Revenue: $705.5 million vs analyst estimates of $675.2 million (14.4% year-on-year growth, 4.5% beat) Adjusted EPS: $0.36 vs analyst estimates of $0.31 (14.9% beat) Adjusted EBITDA: $98.9 million vs analyst estimates of $92.62 million (14% margin, 6.8% beat) Management reiterated its full-year Adjusted EPS guidance of $1.40 at the midpoint Operating Margin: 8.9%, up from 6.3% in the same quarter last year Market Capitalization: $3.95 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Elizabeth Anderson (Evercore ISI) asked about the drivers behind Envista’s recent momentum and challenges in areas gaining traction. CEO Paul Keel cited investments in clinical education, cost controls, and new product development as key, while highlighting macro uncertainty as a persistent challenge. Michael Cherny (Leerink Partners) inquired about the timeline and guidance assumptions for China’s VBP in implants and orthodontics. CFO Eric Hammes said guidance assumes VBP begins in Q2 or Q3, with ongoing monitoring of market developments. Jeffrey Johnson (Baird) questioned the extent of VBP-related headwinds in China and future pricing actions. Keel and Hammes detailed ongoing channel destocking and noted future price increases will be considered if inflation pressures intensify. Michael Sarcone (Jefferies) asked about inflation risks from Middle East tensions and mitigation strategies. Keel explained that fuel and input cost exposures are limited, with task forces in place to manage logistics and s...

Interested in Envista Holdings Corporation? Here are five stocks we like better. Envista delivered a strong Q1, with core growth of 9.5% and all major businesses growing for the fourth straight quarter. Management said the dental market remained resilient despite macroeconomic uncertainty. Margins improved meaningfully, as adjusted gross margin rose to 55.8% and adjusted EBITDA margin expanded to 14%. Adjusted EPS came in at $0.36, and the company reaffirmed its full-year 2026 outlook. Growth was led by product innovation and acquisitions, including double-digit growth in orthodontics, consumables and diagnostics, plus the completed Versah acquisition. Envista also increased its share repurchase authorization by $300 million through 2029. Envista (NYSE:NVST) reported a strong start to 2026, with management citing broad-based growth across its major dental businesses, margin expansion and continued investment in new products and commercial capabilities. On the company’s first-quarter earnings call, President and CEO Paul Keel said Envista posted 9.5% core growth in the quarter, marking the fourth consecutive quarter in which all of its major businesses grew. Orthodontics, consumables and diagnostics each grew double digits, while implants grew mid-single digits excluding China. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? “Q1 was a good start to 2026 for Envista, extending the momentum we built across 2024 and 2025,” Keel said. He added that the dental market continued to show resilience despite macroeconomic volatility, with minimal impact so far from the conflict in the Middle East. Chief Financial Officer Eric Hammes said first-quarter sales were $706 million. Core sales increased 9.5%, while foreign exchange added a little more than 400 basis points. The company’s growth benefited from four additional billing days and a tailwind related to the Spark deferral. → MercadoLibre Boldly Invests in Growth: Discount Deepens Excluding those items, Hammes said core growth was about 4%, which was in line with Envista’s expectations. The additional billing days contributed an estimated $28 million, or 4.5 percentage points of growth, while foreign exchange added about $26 million in revenue. Underlying volume and price contributed another $22 million, and Spark deferral tailwinds added $9 million. Keel said volume contributed more than sev...

Image source: The Motley Fool. Thursday, May 7, 2026 at 5 p.m. ET President & Chief Executive Officer — Paul Keel Chief Financial Officer — Eric Hammes Paul Keel, our President and Chief Executive Officer; and Eric Hammes, our Chief Financial Officer. Before we begin, I want to point out that our earnings release, the slide presentation supplementing today's call and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are available on the Investors section of our website, www.envistaco.com. The audio portion of this call will be archived in the Investors section of our website later today under the heading Events and Presentations. During the presentation, we will describe some of the more significant factors that impacted year-over-year performance. Supplemental materials describe additional factors that impacted our results. Unless otherwise noted, references in these remarks to company-specific financial metrics relate to the first quarter of 2026 and references to period-to-period increases and decreases in financial metrics are year-over-year. During the call, we may describe certain products and solutions that have applications submitted and pending certain regulatory approvals or are available only in certain markets. We will also make forward-looking statements within the meaning of the federal securities laws, including statements regarding events and developments that we believe, anticipate or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law. With that, I'll turn the call over to Paul. Paul Keel: Thanks, Jim. Good afternoon, and welcome, everyone. On today's call, I'll kick us off with a summary of our Q1 performance. Eric will then take us through the numbers in more detail, and I'll wrap things up with some closing thoughts before opening the Q&A. As an overarching statement on the quarter, Q1 was a good start to 2026 for Envista, extending momentum we built across 2024 and '25. As you...

BREA, Calif., May 6, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended April 3, 2026. "We delivered a good start to 2026, with first quarter results reflecting continued strong execution and progress in support of our strategic priorities," said Paul Keel, CEO. "We delivered growth across all our major businesses, driven by customer engagement and new product commercialization. Our 9.5% core revenue growth converted to 25% adjusted EBITDA and 50% EPS growth, while also supporting double-digit increases in R&D and Sales & Marketing investment. With momentum continuing, we are reaffirming our full-year guidance and announcing an incremental $300 million share repurchase program." First Quarter Financial Highlights Sales were $706 million, with core sales growth of 9.5% over the first quarter of 2025. GAAP diluted EPS of $0.23 and adjusted diluted EPS of $0.36 (+50% year-on-year) GAAP Net Income was $39 million and adjusted EBITDA was $99 million (+25% year-on-year), with an adjusted EBITDA margin of 14.0% (+120 bps year-on-year) First Quarter Business Highlights Growth: In the context of macro uncertainty, all major businesses delivered positive growth, with 8.4% core growth in our Specialty Products & Technologies segment and 11.5% core growth in our Equipment and Consumables segment. Operations: Ongoing broad-based contributions from the Envista Business System (EBS) supporting 100 bps of Gross Margin and 120 bps of adjusted EBITDA margin expansion. People: Continued gains in employee engagement and talent development; 3700 patients served through our charitable Envista Smile Project. Net Income, EBITDA, and EPS (in millions, except per share amounts): Cash Flow: Operating cash flow for the first quarter of 2026 was negative $3 million and free cash flow was negative $16 million, compared to $0 million and negative $5 million in the first quarter of 2025, respectively. Share Repurchases: During the quarter ended April 3, 2026, we repurchased 1.6 million shares for approximately $43 million. At the end of the quarter, we had approximately $41 million remaining repurchase capacity under our stock repurchase program. On May 5, 2026, our Board of Directors authorized a new stock repurchase program under which we may repurchase an incremental $300 million of our outstanding common stock through December 3...

For the quarter ended March 2026, Envista (NVST) reported revenue of $705.5 million, up 14.4% over the same period last year. EPS came in at $0.36, compared to $0.24 in the year-ago quarter. The reported revenue represents a surprise of +4.75% over the Zacks Consensus Estimate of $673.52 million. With the consensus EPS estimate being $0.31, the EPS surprise was +16.13%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Envista performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Sales- Equipment & Consumables- Other developed markets: $8.4 million versus $8.91 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.2% change. Geographic Sales- Equipment & Consumables- Emerging markets: $34 million compared to the $30.74 million average estimate based on three analysts. The reported number represents a change of +14.9% year over year. Geographic Sales- North America: $364.2 million versus the three-analyst average estimate of $353.73 million. The reported number represents a year-over-year change of +12.3%. Geographic Sales- Western Europe: $184.8 million versus the three-analyst average estimate of $156.12 million. The reported number represents a year-over-year change of +29%. Geographic Sales- Other developed markets: $31.5 million versus $32.45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.6% change. Geographic Sales- Equipment & Consumables- Western Europe: $30.5 million versus $26.73 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +20.6% change. Geographic Sales- Specialty Products & Technologies- North America: $189.4 million versus $186.87 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change. Geogra...

BREA, Calif. (AP) — BREA, Calif. (AP) — Envista Holdings Corp. (NVST) on Wednesday reported first-quarter earnings of $38.7 million. The Brea, California-based company said it had net income of 23 cents per share. Earnings, adjusted for one-time gains and costs, were 36 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 31 cents per share. The maker of dental products posted revenue of $705.5 million in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $673.5 million. Envista expects full-year earnings in the range of $1.35 to $1.45 per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVST at https://www.zacks.com/ap/NVST

Envista (NVST) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +16.13%. A quarter ago, it was expected that this maker of dental products would post earnings of $0.32 per share when it actually produced earnings of $0.38, delivering a surprise of +18.75%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Envista, which belongs to the Zacks Medical - Products industry, posted revenues of $705.5 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 4.75%. This compares to year-ago revenues of $616.9 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Envista shares have added about 20.6% since the beginning of the year versus the S&P 500's gain of 6%. While Envista has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Envista was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks her...